FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026. The eNRGy trial showed a 36.8% ORR. It also received priority review, breakthrough, and orphan designations.
Acromegaly patients face persistent symptoms including fatigue, joint pain, headaches, and brain fog despite biochemical control. Treatment burden and financial barriers remain significant, particularly in sub-Saharan Africa where diagnostic tools and therapies are often inaccessible.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
The FDA has approved a supplemental new drug application for the combination regimen of Venclexta (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia, supported by Phase 3 AMPLIFY trial data.
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778381 |
National Survey of Chronic Occupational Pain in Thai Anesthesia Providers |
NOT_YET_RECRUITING | |
| NCT07776470 |
Examining the Effectiveness of Ergonomics and Exercise Training in Caregivers |
NOT_YET_RECRUITING | NA |
| NCT07767669 |
A Controlled Study to Evaluate the Effects of a Topical Cream on Symptoms of Arthritis, Joint, and Muscle Pain |
COMPLETED | NA |
| NCT07763925 |
Effects of Pilates and Desk-Based Exercise on Office Workers |
COMPLETED | NA |
| NCT07752381 |
A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery |
COMPLETED | NA |
| NCT07744451 |
Kinesiotaping Versus Physiotherapy for Post-Covid-19 Back Pain |
COMPLETED | NA |
| NCT07705945 |
Using Telehealth to Improve Musculoskeletal Care Through Expanded Physical Therapy Access |
NOT_YET_RECRUITING | NA |
| NCT07688096 |
Regenerative Medicine for Joint Hypermobility and Instability |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07685418 |
Ischemic Compression and Home Exercise in Non-Specific Neck Pain |
RECRUITING | NA |
| NCT07665333 |
Multidisciplinary Health Monitoring for Esports Players |
NOT_YET_RECRUITING | NA |
